Bonvini Ezio 4

What Happened

• Ezio Bonvini, Senior Vice President, Research & CSO of MacroGenics (MGNX), had derivative instruments converted/exercised and was granted restricted stock units (RSUs). On Feb 15, 2026 he exercised/converted 16,665 derivative shares and, to satisfy tax withholding, 6,433 shares were surrendered/withheld (reported value $11,000 at $1.71 per share). On Feb 12, 2026 the filing reports new/recognized RSU grants of 31,250 and 187,500 shares (derivative awards reported at $0.00).

Key Details

• Transaction dates: Feb 12, 2026 (RSU grants); Feb 15, 2026 (exercise/conversion and tax withholding).
• Exercise/conversion reported: 16,665 derivative shares (reported as both acquired and disposed in the filing entries).
• Tax withholding: 6,433 shares withheld/ surrendered at $1.71 per share, totaling $11,000 (transaction code F).
• RSU grants: 31,250 and 187,500 RSUs reported on Feb 12, 2026 (reported as awards, code A, $0.00 per share).
• Footnotes: prior RSU grant (Feb 15, 2023) of 50,000 RSUs vests in three equal annual installments; RSUs convert one-for-one to common stock; another footnote describes a vesting/ exercise cadence (12.5% then 6.25% quarterly).
• Shares owned after the transactions: not specified in the provided filing extract.
• Filing date: Feb 17, 2026 (appears timely relative to reported transaction dates).

Context

• The sequence (exercise/conversion plus withholding of shares to cover taxes) is consistent with a cashless/net settlement or tax withholding on a stock-based award rather than an open-market sale. RSU awards are compensatory and vest over time per the footnotes; they do not by themselves indicate a buy/sell signal. The withheld shares relate to tax obligations, not a discretionary sale for cash.